PMID- 31162772
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 41
IP  - 8
DP  - 2019 Aug
TI  - Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid 
      carcinoma: A systematic review and meta-analysis.
PG  - 2823-2829
LID - 10.1002/hed.25832 [doi]
AB  - INTRODUCTION: The aim of this study is to investigate and summarize the treatment 
      efficacy and adverse effects (AEs) of sorafenib in the treatment of metastatic 
      medullary thyroid carcinomas (MTCs). METHODS: We included studies reporting the 
      treatment efficacy or drug toxicity of sorafenib as a single therapeutic agent in 
      MTCs. Pooled incidence and its 95% confidence interval (CI) for complete 
      response, partial response (PR), stable disease (SD), and sorafenib-related AEs 
      were calculated using random-effect model. RESULTS: Eight trials with 101 
      metastatic MTCs were included for meta-analyses. The overall PR and SD were 21% 
      (95% CI = 9-33) and 58% (95% CI = 41-75), respectively. Hand-foot syndrome, 
      diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension were the most 
      commonly observed AEs. CONCLUSION: Our results show that sorafenib treatment has 
      a modest effect and might be a candidate treatment in patients with metastatic 
      MTCs who have failed other therapeutic regimens.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Vuong, Huy Gia
AU  - Vuong HG
AUID- ORCID: 0000-0001-6213-765X
AD  - Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
FAU - Ho, An Thi Nhat
AU  - Ho ATN
AD  - Department of Medicine, Medstar Harbor Hospital, Baltimore, Maryland.
FAU - Tran, Thao T K
AU  - Tran TTK
AD  - Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, 
      Vietnam.
FAU - Capdevila, Jaume
AU  - Capdevila J
AD  - Medical Oncology Department, Vall d'Hebron University Hospital, Universitat 
      Autonoma de Barcelona, Barcelona, Spain.
FAU - Benekli, Mustafa
AU  - Benekli M
AD  - Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, 
      Turkey.
FAU - Nakazawa, Tadao
AU  - Nakazawa T
AD  - Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
FAU - Katoh, Ryohei
AU  - Katoh R
AD  - Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
FAU - Kondo, Tetsuo
AU  - Kondo T
AD  - Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190604
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Antineoplastic Agents)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - Thyroid cancer, medullary
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/secondary
MH  - Humans
MH  - Sorafenib/adverse effects/*therapeutic use
MH  - Thyroid Neoplasms/*drug therapy/secondary
OTO - NOTNLM
OT  - VEGFR
OT  - adverse effect
OT  - drug toxicity
OT  - medullary thyroid carcinoma
OT  - partial response
OT  - sorafenib
OT  - stable disease
OT  - targeted therapy
EDAT- 2019/06/05 06:00
MHDA- 2020/11/24 06:00
CRDT- 2019/06/05 06:00
PHST- 2018/11/15 00:00 [received]
PHST- 2019/03/03 00:00 [revised]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2019/06/05 06:00 [entrez]
AID - 10.1002/hed.25832 [doi]
PST - ppublish
SO  - Head Neck. 2019 Aug;41(8):2823-2829. doi: 10.1002/hed.25832. Epub 2019 Jun 4.